Aprepitant

CHEMBL1471 Phase 4 Aprovado Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
534.4 g/mol
LogP
4.2
Phase
4

A substance P/neurokinin-1 receptor antagonist that blocks signals in the brain that trigger nausea and vomiting, commonly used to prevent chemotherapy-induced and postoperative nausea. It is often combined with other antiemetic drugs for maximum effectiveness.

Peso Molecular

534,4000 g/mol

LogP

4,20

TPSA

75,20 Ų

Regra dos 5 de Lipinski

Reprovado

Áreas Terapêuticas

Mecanismo de Ação

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mecanismo

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[C@@H](O[C@H]1OCCN(Cc2n[nH]c(=O)[nH]2)[C@H]1c1ccc(F)cc1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1

InChI

InChI=1S/C23H21F7N4O3/c1-12(14-8-15(22(25,26)27)10-16(9-14)23(28,29)30)37-20-19(13-2-4-17(24)5-3-13)34(6-7-36-20)11-18-31-21(35)33-32-18/h2-5,8-10,12,19-20H,6-7,11H2,1H3,(H2,31,32,33,35)/t12-,19+,20-/m1/s1

Molecular Formula

C23H21F7N4O3

HBD / HBA

2 / 12

Ligações Rotacionáveis

6

Átomos Pesados

37

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A substance P/neurokinin-1 receptor antagonist that blocks signals in the brain that trigger nausea and vomiting, commonly used to prevent chemotherapy-induced and postoperative nausea. It is often combined with other antiemetic drugs for maximum effectiveness.

Competitively binds to its target receptor without activating it, blocking the natural ligand from binding and preventing receptor-mediated signaling.

Yes, Aprepitant is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1471. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 135413536. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.